Core Viewpoint - The company has approved a strategic plan for 2026-2030 to adapt to macroeconomic changes and technological transformations, aiming to strengthen its market position and drive growth [1][2]. Group 1: Board Meeting Details - The board meeting was held on October 15, 2025, in Shanghai, with all 9 directors present, including participation via communication methods [1]. - The meeting was chaired by Chairman Deng Haibin, with all senior executives in attendance [1]. Group 2: Strategic Planning - The strategic plan focuses on two main growth curves: enhancing the existing pharmaceutical business through management improvements and acquisitions, and exploring new opportunities for innovation and development [2]. - The property management sector will continue to operate steadily, contributing stable cash profits to support both growth curves [2]. - The company aims to achieve high-quality development and continuous value growth through a dual strategy of "industrial operation + investment and mergers" [2].

Group 1 - The board of directors of Shanghai Haixin Group Co., Ltd. held its 13th meeting of the 11th session on October 15, 2025, in accordance with relevant laws and regulations [2][3] - The meeting was attended by all 9 directors, with some participating via communication methods [2] - The board unanimously approved the strategic plan for 2026-2030, focusing on strengthening the company's core business and exploring new growth opportunities through mergers and acquisitions [3] Group 2 - The strategic plan aims to adapt to macroeconomic changes and industry transformations while enhancing the company's operational capabilities [3] - The company will pursue a dual strategy of "industrial operation + investment and mergers" to drive innovation and high-quality development [3] - The property management sector is expected to continue providing stable cash flow to support the company's growth initiatives [3]

Group 1 - Company held its 13th meeting of the 11th board of directors on October 15, 2025, in Shanghai, discussing strategic planning documents [1] - For the year 2024, the revenue composition of the company is as follows: pharmaceutical manufacturing accounts for 54.76%, trading business for 17.33%, textile industry for 14.83%, and other businesses for 13.08% [1] - The current market capitalization of the company is 8.1 billion yuan [2]

一、董事会会议召开情况 （一）本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性 文件和公司章程的规定； （二）本次董事会会议通知于 2025 年 9 月 29 日以书面方式向全体董事发出， 会议资料于同日以书面方式向全体董事发出； 证券代码：600851/900917 证券简称：海欣股份/海欣B股 公告编号：2025-032 上海海欣集团股份有限公司 第十一届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为积极应对国内外宏观环境变化、产业变迁与技术变革的发展趋势，把握新 时代重要战略机遇，上海海欣集团股份有限公司（以下简称公司）以做优做强上 1 市公司为基本目标，制定了《上海海欣集团股份有限公司战略规划（2026 年—2030 年）》，全面规划公司未来五年的发展方向与目标。 未来五年，公司将秉持稳中求进的总基调，强化产业运营和投资并购，在战 略选择上，一方面，坚持从实际出发，依托已有的医药产业基础持续深耕，通过 内强管理、深挖潜能和外延并购扩张，推动资源整合和业务升级，努力做大做强 ...

Group 1 - The company has approved an investment of up to 30 million RMB in the Yuanhe Puhua Industrial M&A Fund, considering the fund's risk diversification and the management's strong investment capabilities [2][3] - The company, along with its wholly-owned subsidiary, has committed 30 million RMB to the fund, becoming a limited partner in the partnership [2] - The partnership has successfully raised a total of 2.473 billion RMB for the fund, with the partnership term extended from eight years to ten years [4][5] Group 2 - The fund has completed the necessary registration and filing with the China Securities Investment Fund Industry Association, with a registration date of September 27, 2024, and a change date of October 9, 2025 [5] - The fund is managed by Yuanhe Puhua Tongxin (Suzhou) Investment Management Co., Ltd., and the custodian is Industrial and Commercial Bank of China [5]

Group 1 - The company has approved an investment of up to 30 million RMB in the Yuanhe Puhua Industrial M&A Fund, considering the fund's risk diversification and past investment returns [2] - As of June 20, 2025, the company and its wholly-owned subsidiary have committed 30 million RMB to the fund and are acting as limited partners [3] - The fund has successfully raised a total of 2.473 billion RMB, with the partnership term extended from eight to ten years [4] Group 2 - The fund is registered with the China Securities Investment Fund Industry Association, with a registration date of September 27, 2024, and a change date of October 9, 2025 [4][5] - The management of the fund is handled by Yuanhe Puhua Tongxin (Suzhou) Investment Management Co., Ltd., and the custodian is Industrial and Commercial Bank of China [4]

证券代码：600851 证券简称：海欣股份 公告编号：2025-031 900917 海欣 B 股 上海海欣集团股份有限公司 关于投资产业基金项目的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 投资标的名称 | 安徽高新元禾璞华私募股权投资基金合伙企业 | | | | | --- | --- | --- | --- | --- | | | （有限合伙） | | | | | 投资金额（万元） | 3,000 | | | | | 投资进展阶段 | 完成 | 终止 | 交易要素变更 | 进展 | | 特别风险提示（如有请勾选） | 募集失败 | | | | | | 未能完成备案登记 | | | | | | 提前终止 | | | | | | 发生重大变更 | | | | | | 其他：本次投资过程中可能受到包括但不限 | | | | | | 于政策法规、宏观经济、行业周期、市场变化、 | | | | | | 投资标的运营管理等多种因素的影响，存在基 | | | | | | 金投资收益不 ...

Group 1 - The core announcement involves a tender for the renovation project of the third floor of Shanghai Century Hui by Changjiang Securities Co., Ltd., with a budget of 5.4089 million yuan [1] - The project is set to be published on September 25, 2025, indicating a future investment opportunity in the construction and renovation sector [1] - The ownership structure of Changjiang Securities shows that it is held by Hubei Energy and Haixin Co., with respective stakes of 9.58% and 4% [1]

Group 1 - The core viewpoint of the article highlights the recent developments in HaiXin Co., Ltd.'s pharmaceutical sector, particularly in the area of oncology drug research and development [1] - The chairman of HaiXin Co., Ltd., Deng Haibin, stated that the company's pharmaceutical subsidiaries are primarily traditional generic drug companies, focusing on post-marketing clinical trial evaluations of existing key products and promoting the consistency evaluation of generic drugs [1] - Regarding the clinical trial progress of HaiXin Biotech's APDC, it was mentioned that the design of the Phase III clinical trial was established a long time ago, leading to difficulties in patient enrollment, and the company is currently exploring solutions to this issue [1]

Group 1 - The company, Haixin Co., Ltd. (600851.SH), announced the intention to transfer the drug approval documents held by its subsidiary, Xi'an Haixin Pharmaceutical Co., Ltd., due to weak profitability and high asset-liability ratio [1] - The company holds a 55% stake in Xi'an Haixin and aims to maximize asset value and recover funds through this transfer [1] - Xi'an Haixin will maintain its current drug production and sales operations until the transfer target for the drug approval documents is determined [1]